The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown.
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
Metra, Marco;Li, Jing;
2021-01-01
Abstract
The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
GALACTIC_HF_Main_NEJM_2020.pdf
solo utenti autorizzati
Tipologia:
Documento in Pre-print
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
608.11 kB
Formato
Adobe PDF
|
608.11 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
